Tradestie Institutional Equity Comparison Engine

RBOT.WS vs ENOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENOV Overall Edge

ENOV Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Enovis Corporation (ENOV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RBOT.WS trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ENOV at 7.3x Forward P/E and 4.0% operating margin (+1.8% YoY). In options structure, RBOT.WS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENOV sits in UNCLASSIFIED (43rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ENOV
RBOT.WS N/M vs ENOV 7.3x Fwd P/E
Growth & Margin Winner ENOV
Op Margin N/A vs 4.0% ยท YoY N/A vs +1.8%
Momentum & Technical Winner ENOV
1Y -67.2% vs -6.3% ยท 52W Pos 0% vs 59%
Options & Structure Winner ENOV
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (43rd %ile IV)
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
1M Return -67.2%
1Y Return -67.2%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
ENOV NYSE
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$25.47
-2.9% 1D
Market Cap $1.5B
1M Return +17.97%
1Y Return -6.26%
Forward P/E 7.3x
Unified AI Score
30.0 / 100 SELL
Tech 15.0 Fund 28.0 Flow 50.0 Mom 21.3

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RBOT.WS -67.2% ENOV -6.26% Spread: +65.93 pp (ENOV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RBOT.WS TTM Op. Margin: N/A ENOV TTM Op. Margin: 4.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ENOV. Trailing 12-month operating profitability (RBOT.WS N/A vs ENOV 4.0%) and valuation multiples (RBOT.WS N/M vs ENOV 7.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RBOT.WS (1) vs ENOV (9)
Institutional Metric RBOT.WS ENOV Criterion Row Winner
Market Capitalization Scale N/A $1.5B Larger Scale ENOV
Trailing P/E Ratio Valuation N/M 7.5x Lower Multiple ENOV
Forward P/E Ratio Valuation N/M 7.3x Lower Multiple ENOV
Revenue Growth (YoY) Growth N/A +1.8% Higher Growth ENOV
Operating Margin (TTM) Profitability N/A 4.0% Higher Margin ENOV
Net Profit Margin Profitability N/A -22.9% Higher Margin ENOV
Return on Equity (ROE) Capital Efficiency N/A -29.9% Higher ROE ENOV
52-Week Range Position Momentum 0% ($0โ€“$0) 59% ($17โ€“$32) Stronger Trend ENOV
Beta / 30D Volatility Risk Regime N/A 0.75ฮฒ ยท 101% Vol Lower Realized Risk ENOV
Unified Institutional Score Composite Signal 50.1 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite RBOT.WS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RBOT.WS vs ENOV Buy Guide
RBOT.WS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RBOT.WS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ENOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 43rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RBOT.WS nor ENOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.